Recently, the phase III PACIFIC trial that randomized locally-advanced unresectable non-small cell lung cancer (NSCLC) patients to either adjuvant durvalumab (anti-PD-L1 antibody) or placebo after chemoradiation demonstrated significant improvement in progression-free survival with durvalumab (median survival 16.8 vs. 5.6 months) [121]. Here, CD274 is linked to non-small cell lung carcinoma.